Industry news that matters to you.  Learn more

Indiana CTSI, GVK Biosciences Partner to Provide National Access to Biomarkers Database

Reading time: 2 minutes

The Indiana Clinical and Translational Sciences Institute (CTSI), a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond, announced on Friday that they have partnered with GVK Biosciences. GVK Biosciences will provide researchers across the United States access to their clinical biomarker database.

The GVK Biosciences clinical biomarker database, known as GOBIOM, is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 12,000 biomarkers comprising biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. The biomarker database will be available nationwide to 55 medical centers and universities supported by the Clinical and Translational Sciences Award from the National Institutes of Health.

The Indiana CTSI Bioinformatics Core and Indiana Institute for Personalized Medicine will work together to manage the process by which researchers access this new resource.

Anantha Shekhar, director of the Indiana CTSI, said:

The GOBIOM database is a powerful tool for clinicians and researchers looking to mine the most up to date and comprehensive information about any putative biomarker for personalized therapeutics. The Indiana CTSI is very pleased to partner with GVK BIO and the Indiana Institute for Personalized Medicine to make this resource available to all clinical and translational researchers in the national consortium. I am also grateful to the Indiana Economic Development Corporation for facilitating the GVK BIO and CTSI partnership.

The partnership follows a few months after GVK Biosciences extended its biomarker database license to the US Food and Drug Administration (FDA).

Source: Indiana CTSI